Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00916162 · ClinicalTrials.gov registry record
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 24
- Enrollment target
NCT00916162: Completed study, sponsored by Massachusetts General Hospital.
NCT00916162 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00916162 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The purpose of this research study is to study the effects of stopping aromatase inhibitory (AI) therapy on breast cancer progression. Aromatase inhibitors are a class of drugs used to treat breast cancer in postmenopausal women. They work by decreasing the level of estrogen, which is believed to stimulate the growth of tumor tissue. Breast cancer that progresses despite therapy with an AI is thought to have been resistant to AI therapy. There is scientific evidence to suggest that resistant breast cancer cells learn to grow at the very low levels of estrogen present on AI therapy and that increasing estrogen levels even slightly by stopping AI therapy with inhibit the breast cancer cells. An improvement or stabilization of breast cancer has been observed after stopping therapy with tamoxifen, a different anti-estrogen therapy, and has been reported in the literature after stopping AI therapy. This research study will be the first study to formally test the rate of disease improvement (response) or stabilization after stopping AI therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00916162
The ClinicalTrials.gov registry entry for NCT00916162 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00916162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00916162 about?
NCT00916162 is a clinical study titled "Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy". The purpose of this research study is to study the effects of stopping aromatase inhibitory (AI) therapy on breast cancer progression. Aromatase inhibitors are a class of drugs used to treat breast cancer in postmenopausal women. They work by decreasing the level of estrogen, which is believed to st...
What is the current status of trial NCT00916162?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2006-08. Estimated completion is 2010-01.
Who is sponsoring clinical trial NCT00916162?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.